We’re honored to receive a grant from BPI France for our imaging projects.

MRI, CT scans, and PET scans, which require the injection of a tracer into the patient, are effective techniques for detecting serious diseases such as cancer. These tracers are slightly toxic or radioactive, limiting their use in frail individuals. A new technique based on molecules labeled with non-radioactive isotopes is currently being developed worldwide. CortecNet is developing innovative synthesis pathways for these new tracers, with small-scale production at chemical grade. The goal here is to set up a large-scale production facility that meets the standards required for use in humans.

This recognition fuels our mission to innovate and strengthen local production.